Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal Cells.
cell therapy
malignant pleural mesothelioma (MPM)
mesenchymal stromal cells
mesothelioma
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
08 06 2021
08 06 2021
Historique:
received:
26
03
2021
revised:
01
06
2021
accepted:
04
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
30
10
2021
Statut:
epublish
Résumé
Malignant Pleural Mesothelioma (MPM) is an aggressive tumor that has a significant incidence related to asbestos exposure with no effective therapy and poor prognosis. The role of mesenchymal stromal cells (MSCs) in cancer is controversial due to their opposite effects on tumor growth and in particular, only a few data are reported on MSCs and MPM. We investigated the in vitro efficacy of adipose tissue-derived MSCs, their lysates and secretome against different MPM cell lines. After large-scale production of MSCs in a bioreactor, their efficacy was also evaluated on a human MPM xenograft in mice. MSCs, their lysate and secretome inhibited MPM cell proliferation in vitro with S or G0/G1 arrest of the cell cycle, respectively. MSC lysate induced cell death by apoptosis. The efficacy of MSC was confirmed in vivo by a significant inhibition of tumor growth, similar to that produced by systemic administration of paclitaxel. Interestingly, no tumor progression was observed after the last MSC treatment, while tumors started to grow again after stopping chemotherapeutic treatment. These data demonstrated for the first time that MSCs, both through paracrine and cell-to-cell interaction mechanisms, induced a significant inhibition of human mesothelioma growth. Since the prognosis for MPM patients is poor and the options of care are limited to chemotherapy, MSCs could provide a potential new therapeutic approach for this malignancy.
Sections du résumé
BACKGROUND
Malignant Pleural Mesothelioma (MPM) is an aggressive tumor that has a significant incidence related to asbestos exposure with no effective therapy and poor prognosis. The role of mesenchymal stromal cells (MSCs) in cancer is controversial due to their opposite effects on tumor growth and in particular, only a few data are reported on MSCs and MPM.
METHODS
We investigated the in vitro efficacy of adipose tissue-derived MSCs, their lysates and secretome against different MPM cell lines. After large-scale production of MSCs in a bioreactor, their efficacy was also evaluated on a human MPM xenograft in mice.
RESULTS
MSCs, their lysate and secretome inhibited MPM cell proliferation in vitro with S or G0/G1 arrest of the cell cycle, respectively. MSC lysate induced cell death by apoptosis. The efficacy of MSC was confirmed in vivo by a significant inhibition of tumor growth, similar to that produced by systemic administration of paclitaxel. Interestingly, no tumor progression was observed after the last MSC treatment, while tumors started to grow again after stopping chemotherapeutic treatment.
CONCLUSIONS
These data demonstrated for the first time that MSCs, both through paracrine and cell-to-cell interaction mechanisms, induced a significant inhibition of human mesothelioma growth. Since the prognosis for MPM patients is poor and the options of care are limited to chemotherapy, MSCs could provide a potential new therapeutic approach for this malignancy.
Identifiants
pubmed: 34201002
pii: cells10061427
doi: 10.3390/cells10061427
pmc: PMC8227879
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Stem Cell Res Ther. 2016 Feb 09;7:25
pubmed: 26861734
Pharmaceutics. 2020 Apr 30;12(5):
pubmed: 32365861
J Thorac Oncol. 2018 Sep;13(9):1269-1283
pubmed: 29966799
Cytotherapy. 2015 Dec;17(12):1687-95
pubmed: 26481416
Cancer Gene Ther. 2015 Jan;22(1):44-54
pubmed: 25525034
Acta Biochim Biophys Sin (Shanghai). 2011 Feb;43(2):143-8
pubmed: 21196449
Oncol Lett. 2016 Feb;11(2):1089-1094
pubmed: 26893697
Blood. 2009 Apr 30;113(18):4197-205
pubmed: 19036701
J Exp Clin Cancer Res. 2015 May 20;34:52
pubmed: 25986392
Clin Cancer Res. 2009 Dec 1;15(23):7175-85
pubmed: 19920103
Cancer Biol Med. 2017 May;14(2):129-141
pubmed: 28607804
Microsc Res Tech. 2015 Apr;78(4):249-54
pubmed: 25639567
Sci Rep. 2018 May 16;8(1):7716
pubmed: 29769543
Br J Cancer. 1999 Feb;79(3-4):666-72
pubmed: 10027347
Biomed Pharmacother. 2017 Mar;87:755-758
pubmed: 28153512
Exp Mol Pathol. 2003 Dec;75(3):248-55
pubmed: 14611816
Stem Cell Res Ther. 2014 May 06;5(3):63
pubmed: 24887516
J Clin Oncol. 2009 Jun 20;27(18):3007-13
pubmed: 19364962
Curr Res Transl Med. 2019 Feb;67(1):20-27
pubmed: 30104160
PLoS One. 2011;6(12):e28321
pubmed: 22205945
Front Bioeng Biotechnol. 2020 Feb 05;8:43
pubmed: 32117924
Stem Cell Res Ther. 2018 Dec 7;9(1):336
pubmed: 30526687
Leukemia. 2007 Feb;21(2):304-10
pubmed: 17170725
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Nat Clin Pract Oncol. 2008 Mar;5(3):136-47
pubmed: 18227828
Ecancermedicalscience. 2017 Feb 23;11:721
pubmed: 28275390
Cell Tissue Bank. 2019 Sep;20(3):423-434
pubmed: 31338647
Stem Cells Int. 2017;2017:4960831
pubmed: 28642794
J Exp Clin Cancer Res. 2019 May 28;38(1):222
pubmed: 31138260
J Exp Clin Cancer Res. 2017 Dec 04;36(1):174
pubmed: 29202823
Br J Cancer. 2012 Jun 5;106(12):1901-6
pubmed: 22596239
Thorax. 2014 Jul;69(7):638-47
pubmed: 24567297
Transl Lung Cancer Res. 2015 Feb;4(1):55-66
pubmed: 25806346
Sci Rep. 2017 Aug 24;7(1):9376
pubmed: 28839168
Anticancer Agents Med Chem. 2017 Nov 24;17(11):1578-1585
pubmed: 28356007
J Pathol. 2020 Apr;250(5):555-572
pubmed: 31608444
J Cell Physiol. 2012 Jan;227(1):44-58
pubmed: 21412769
J Extracell Vesicles. 2017 Jan 18;6(1):1265291
pubmed: 28326166
Int J Stem Cells. 2009 May;2(1):59-68
pubmed: 24855521
Int J Hematol Oncol Stem Cell Res. 2015 Apr 1;9(2):95-103
pubmed: 25922650
Stem Cells Dev. 2017 Feb 1;26(3):206-214
pubmed: 27762666
Cancer Lett. 2009 Jul 18;280(1):31-7
pubmed: 19285791
Leukemia. 2019 Mar;33(3):597-611
pubmed: 30705410
Cell Death Differ. 2005 Oct;12(10):1344-57
pubmed: 15905878